Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 14/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765489 | 0.90 | F2 (0.39) | CASP1NTRK1AVPR1BNTRK3ELANE | |
| SCHEMBL30766049 | 0.88 | NTRK1 (0.43) | CASP1NTRK1AVPR1BNTRK3ELANE | |
| SCHEMBL30765550 | 0.88 | F2 (0.38) | CASP1NTRK1AVPR1BNTRK3ELANE | |
| Hydrochloric Acid SCHEMBL30765434 | 0.88 | NTRK1 (0.43) | CASP1NTRK1AVPR1BNTRK3ELANE | |
| SCHEMBL30765437 | 0.87 | HDAC6 (0.41) | ELANECMA1CTRC | |
| SCHEMBL30765886 | 0.86 | CASP1 (0.40) | CASP1NTRK1AVPR1BNTRK3ELANE | |
| SCHEMBL30765820 | 0.86 | CMA1 (0.40) | NTRK1ELANECMA1CTRC | |
| SCHEMBL30765583 | 0.86 | F2 (0.40) | NTRK1NTRK3CMA1CTRC | |
| SCHEMBL30765911 | 0.86 | ELANE (0.40) | CASP1NTRK1AVPR1BNTRK3ELANE | |
| SCHEMBL30765749 | 0.86 | F2 (0.38) | NTRK1NTRK3CMA1CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |